Table 1 shows the characteristics of the model baseline patient population, which is based on the Phase III clinical trial population (2) Age-specific and gender, base line Virologic load, baseline CD4 count and ethnicity from clinical trial data and published literature. Patients who progressed (due to virologic failure) had a viral load of ≥50 copies/mL were categories to no response to treatment. Patients who received therapy and achieved ≤ 50 copies of viral RNA were categorized to effective response to treatment. Using the data, the probability of efficacy of drugs were calculated. GENVOYA showed probability of 0.83 efficacy compared to STRIBLID which only showed 0.79 efficacy (3). There was not much significant difference in the efficacy …show more content…
Treatment for HIV continued with additional costs for treatment with bisphosphonates. Rates of adverse events were based on clinical trial III and were included in the model after being converted to 96 week probabilities.
Costs per 96-week cycle are shown in Figure 3 were inflated to 2015 dollars using the Consumer Price Index. The analysis was conducted from the payer perspective, with included costs as follows: drug cost, treatment for adverse events(bisphosphonate) and cost of alternative therapy(ATRIPLA). Costs of productivity losses were not included. Drug costs were based on annual wholesale cost. Regimen dosing schedules were based on published guidelines. In the base case, we evaluated the cost in each arm(figure3)
Table 2 shows the average efficacy and average cost of each drug. GENVOYA had around 5% more efficacy then STRIBLID. The average cost of GENVOYA was $4797 more compared to STRIBLID and the cost effective ratio was $75920 and $73127 respectively for GENVOYA and STRIBLID. Incremental cost effective ratio was(ICER) were calculated as the ratio of incremental costs to incremental efficacy and reported over 96 weeks. the ICER was $141,076.47 when GENVOYA was compared to STRIBLID for 96 weeks. When STRIBLID and GENVOYA were assumed to have equivalent efficacy to reflect the noninferiority clinical trial findings. GENVOYA showed